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Species Differences in Pharmacokinetics
and Drug Teratogenesis
by Heinz Nau*
Interspecies differences in regard to the teratogenicity of drugs can be the result of differing pharma-
cokinetic processes that determine the crucial concentration-time relationships in the embryo. Maternal
absorption, as well as distribution, ofthe drugs does not usually show great species differences. The first-
pass effect after oral application is often more pronounced in animals than man (e.g., valproic acid, 13-
cis-retinoic acid), although in some cases the reverse was found (e.g., hydrolysis ofvalpromide). Existing
differences can be adjusted by appropriate choice of the administration route and measurements ofdrug
levels. Many variables determine the placental transfer of drugs: developmental stage, type of placenta,
properties ofthe drug. Even closely related drugs (e.g., retinoids) may differ greatly in regard to placental
transfer. Maternal protein binding is an important determinant ofplacental transfer, since only the free
concentration in maternal plasma can equilibrate with the embryo during organogenesis; this parameter
differs greatly across species (e.g., valproic acid: five times higher free fractions in mouse and hamster
than in monkey and man). The metabolic pattern has not yet been demonstrated to be a major cause of
species differences, although recent evidence on phenytoin and thalidomide support the hypothesis that
some species differences can be the result of differing activation/deactivation pathways. Laboratory an-
imals usually have a much higher rate of drug elimination than man. Drastic drug level fluctuations are
therefore present during teratogenicity testing in animals, but not to the same degree in human therapy.
It must, therefore, be investigated ifpeak concentrations (such as for valproic acid and possibly caffeine)
or the area under the concentration-time curve (AUC) (such as for cyclophosphamide and possibly reti-
noids) correlate with the teratogenic response. Only then is a rational and scientific basis for interspecies
comparison possible. It is concluded that the prediction of the human response based on animal studies
can be improved by consideration of the appropriate pharmacokinetic determinants.
Introduction
The extrapolation of teratogenicity studies of drugs
or chemicals from one animal species to another, in par-
ticular from experimental animals to man, remains to
be very problematic (1-3). Great species diffe-rences,
largely unexplaijed up to now, are the rule rather than
the exception. Established human teratogens such as
thalidomide, trimethadione, lithium, and warfarin have
induced a poor teratogenic response in rats. On the
other hand, nonhuman primates, which closely parallel
the human response with regard to the teratogenicity
of thalidomide, norethindrone, testosterone, diethyl-
stilbestrol and methylmercury (1), fail to respond to
methotrexate, a potent human teratogen (4). While all
human teratogens (except the coumarin anticoagulants)
were shown to be teratogenic in at least one animal
species, it is difficult to state at this time which-animal
species is to be preferred in risk assessment studies. It
appears, however, that the rabbit and, particularly, the
monkey offer greater predictability of the human situ-
ation than other species (1,5). The largest number of
compounds tested was shown to be teratogenic in the
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Table 1. Teratogenic doses ofvalproic acid in several species.
Teratogenic dose, mg/kg/daya
Neural tube Skeletal
Species defects defects Route References
Man 30 20-30 Oral (6-8)
Monkey Not observed 150 Oral (9,10)
Rabbit Not observed 150 Oral (11)
Rat Not observed 150 Oral (12)
Hamster 300 Not investigated IP (13)
Mouse 200 200 IP (15)
250 SC (16)
400 Oral (17,18)
'The lowest daily dose with teratogenic outcome is listed.
mouse and hamster, on the other hand, which may in-
dicate numerous "false positive" results (1,2).
Both the type of malformation produced as well as
the teratogenic dose levels used may show drastic spe-
cies differences. Valproic acid was shown to produce
neural tube defects in man (spina bifida), mouse, and
hamster (exencephaly), but not in the monkey, rabbit,
and rat (Table 1). The doses resulting in human tera-
togenicity were shown to be in the upper therapeutic
range (6), which was still five to ten times lower than
teratogenic doses in experimental animals (Table 1).H. NAU
Table 2. Teratogenic doses of retinoids in several species.a
Lowest teratogenic dose
All-trans- 13-cis-Reti-
Species retinoic acid noic acid EtrE
Man ?
Monkey 7.5-40
Rabbit 6
Hamster 7
Rat 6
Mouse 3
aData from refs. 19-31.
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Retinoids produce a rather characteristic and uniform
pattern of malformations, particularly involving the
central nervous system, cardiac and facial structures in
essentially all species investigated. Yet the teratogenic
dose for isotretinoin (13-cis-retinoic acid) in mouse or
rat differed from that in man by a factor of 100 (Table
2) (20,21). On the other hand, interspecies variation of
teratogenic doses ofother retinoids was much less pro-
nounced (Table 2).
There appear to be two major reasons for the ob-
served species differences in response to teratogens:
(a) intrinsic sensitivities ofthe developingtissues, e.g.,
extreme rarity ofneural tube defects in nonhuman pri-
mates, but prominence in most other species including
man; (b) differences in exposure of the embryo during
the sensitive stages of gestation.
This review will be mainly concerned with aspect (b),
although pharmacokinetic studies arejust as important
in regard to aspect (a): intrinsic sensitivities ofthe em-
bryos can only be evaluated at comparable exposure
levels.
The main hypothesis to be evaluated can be stated as
follows: Differences between species in regard to the
teratogenic response to drugs or other chemicals may
be the result of differing processes that determine the
crucial concentration-time relationships in the embryo:
maternal absorption, distribution, plasma and tissue
binding, elimination via metabolism or excretion (bili-
ary, renal...); placental transfer; embryo distribution
and tissue binding, metabolism.
Thus, a number of pharmacokinetic parameters are
important determinants of the drug exposure of the
embryo. Since all of these factors may show consider-
able interspecies variations, it is not surprising that the
resulting drug concentrations in the embryo-and thus
the teratogenic response-may vary greatly from one
species to another. It will be demonstrated, however,
that species differences are particularly pronounced in
regard to drug elimination rates and in regard to ma-
ternal plasma protein binding and placental transfer.
The organogenesis period will be considered wherever
possible, since this is the most relevant gestational pe-
riod in regard to teratogenesis.
Maternal Absorption, Administration
Route, First-Pass Effect
The rate as well as extent of absorption can vary
depending on the species examined, the route ofadmin-
FIGURE 1. Concentration-time curves ofvalproic acid after oral and
SC administration in pregnant mice (left) (17,35) and 13-cis-reti-
noic acid after oral and IV administration in nonpregnant mice
(right); the dataforthe construction ofthe right panel were taken
from Wang et al. (37) and Kalin et al. (36). Note the lowered
bioavailability of both drugs after oral administration.
istration, and the drugformulation used. Since the main
site for drug absorption is often the small intestine, the
stomachemptyingtime maybecomeimportant: thehalf-
life times for emptying are in order of 10 min in mice
and rats, 30minin rabbits, 1-2 hrin dogs and man (33).
Thus, absorption may often be more rapid in rodents
as compared to man. Indeed, following oral administra-
tion of a solution of sodium valproate, maximal plasma
concentrations of valproate were observed between 10
min and 30 min in the mouse (Fig. 1, left panel), but
between 1 and 3 hrin man (34). Administration ofstom-
ach acid-resistant capsules in man resulted in a further
delay of absorption of up to several hours.
The blood, which perfuses the site oforal absorption
(stomach, intestinaltract) must first pass the liverprior
to entering the systemic circulation; therefore, a sig-
nificant portion of the absorbed drug can already be
eliminated via hepatic metabolism during this initial
liver passage (first-pass effect or presystemic clear-
ance). Since the rate of hepatic metabolism in experi-
mental animals often greatly exceeds that in man (see
below), the first-pass effect maysignificantly reduce the
fraction of the dose administered to experimental ani-
mals. Two examples are given in Figure 1. Oral admin-
istration of valproic acid in mice resulted in about 50%
lower drug levels than subcutaneous application (Fig.
1, left panel); the oral bioavailability in man is essen-
tially 100%. The area under the concentration-time
curve (theAUC valueis agood parameterofthe amount
of drug reaching the systemic circulation) of orally ad-
ministered isotretinoin (13-cis-retinoic acid) was found
to be only about one-fifth of the AUC value after IV
application (Fig. 1, right panel). A much lower differ-
ence was found between the AUC (oral) and AUC (IV)
valuefortretinoin (all-trans-retinoic acid) (37,38). Thus,
only 20% ofthe oraliy administered dose ofisotretinoin
is available to the general circulation of the mouse,
which may in part explain the much lower teratogenic
potency ofisotretinoin as compared to tretinoin in that
species (Table 2); another, probably even more impor-
h
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tant reason was recently found to be the surprisingly
low placental transfer ofisotretinoin in the mouse (21).
In some cases, however, the human may exhibit a
more pronounced first pass effect than experimental
animals. Valpromide is rapidly hydrolyzed to valproic
acid after oral administration in man, probably already
in the stomach and intestinal mucosa as well as in the
liver during absorption (39). Due to this very extensive
first-pass effect, minimal amounts of unchanged drug
reached the central circulation and valpromide can be
regarded as a prodrug of valproic acid in man. On the
other hand, valpromide is a major drug component in
the plasma of mice (40) and dogs (41). Teratological
studies with valpromide in experimental animals have
therefore little relevance to the therapeutic situation.
In general, differences in the extent and rate of ab-
sorption are not that drastic, because diffusion ofdrugs
across epithelial membranes is similar in most species.
In any event, such differences can be adjusted if not
only the doses, but the concentrations reached in the
organism, are considered. Because ofthe lower plasma
concentrations obtainedafteroraldosingofvalproicacid
(Fig. 1), larger doses must be administered with this
route to obtain a teratogenic response comparable to
that obtained with SC dosing (17). If drug concentra-
tions rather than drug doses are related to the terato-
genic response, a completely different picture emerges:
comparable drug concentration, regardless if reached
by oral or subcutaneous application, results in compa-
rable teratogenicity. Further, it will be interesting to
evaluate iftretinoin and isotretinoin elicit a comparable
teratogenic response at comparable embryo exposure;
experiments performed in vitro, when both substances
are indeed ofcomparable toxicity, point into this direc-
tion (21,30).
An increasing body of evidence suggests that intra-
peritoneal administration (IP) of drugs can result in
significantly higher embryo/fetus concentrations than
other administration routes. This was shown to be the
case for 2,3,7,8-tetrachlorodibenzo-p-dioxin (42), alkyl-
ating agents (43), piperacillin (131), ethanol (132), and
methadon (133) experiments with exterionized uterine
horns of the rat suspended in drug solutions suggest a
direct transuterine passage ofdrugs (133). Since an un-
known portion ofthe dose injected IP may also pass the
liver prior to entering the systemic circulation, the pos-
sible variability of the resulting first pass effect (if ap-
plicable for a particular drug) adds to the notion that
IP administration is a particularly unsuitable method of
drug administration from the pharmacokinetic view-
point.
Distribution Volume of Drugs
After the drugs are absorbed and maximal concen-
trations are reached in the plasma (Cmax), one, two, or
more elimination phases follow (Fig. 2). If very rapid
equilibrium is reached within the entire organism, then
only one concentration decay phase may be observed
(Fig. 1, valproic acid and, with reservations, isotreti-
Plasma level
Peak concentration
Distribution
Absorption
AUC
Time after Dose
FIGURE 2. Simulated plasma concentration-time curve indicating
absorption, distribution and elimination phases. Note the two
phases of plasma concentration-decay: the first phase (a) corre-
sponds to elimination ofthe drugplus its additional transportfrom
plasma into tissues; the second phase (3) can be related to elimi-
nation only.
noin). For such drugs, the distribution volume can be
calculated from the dose D, the AUC value and the
elimination constant ke:
Vd= D [(AUC)ke]
In most cases, the plasma level decay curve follows two
phases, the distribution phase a (wherethedrugiselim-
inated and is transferred into tissues) and the elimi-
nation phase 1B (pure elimination; diffusion equilibrium
between plasma and tissues). The distribution volume,
Vd,p, duringthe elimination phase is calculated fromthe
dose D, the AUC value, and the elimination constant 1:
Vd, =[(AUC)P]
Some drugs may be stored in a "deep" or "very deep"
compartment in the body which may be represented in
the plasma decay curve as one or two further "bends"
(the -y or 8-phases). Corresponding plasma levels are
usually very low and difficult to detect during these
phases after single drug administration. These stores
are slowly filled up during multiple drug therapy be-
cause diffusionfromplasmaintothestoragesitesisvery
slow. However, once these storage sites have been
loaded with drugs (itmaytake severalweeks oftherapy
in the human), these sites represent a large drug res-
ervoir, which can be slowly released following discon-
tinuation of therapy. A good example for such phar-
macokinetics is etretinate, which was found to be
efficiently stored in human fat (44). Even several
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months after discontinuation of therapy, plasma levels
ofetretinate and itsmetabolite etretincouldbedetected
(45). In one case, conception three months afterthe last
intake ofetretinate mayhaveresultedinamalformation
with plasma drug levels measurable at about 5 ng/mL
(32).
The drug distribution volumes, adjusted for body
weight, generally do not appear to differ profoundly
between species. Examples in Figure 3 demonstrate
that the distribution volumes oftrimethadione and val-
proic acid are rather similar across species. Data on a
number of other drugs also indicate that differences
between the drug distribution volumes in various spe-
cies are limited usually below a factor of 2-3; larger
differences are rare.
Since many drugs exhibit interspecies similarities in
regard to absorption and distribution processes, the
maximalconcentrations (Cmax)reached-particularlyof
those drugs which are rapidly absorbed-are also not
expected to greatly vary across species (unless there
are differences in first pass effect; cf. example of val-
proic acid and isotretinoin, Fig. 1) if comparable doses
are administered, because
D
Cmax = Vd
(for drugs with a single plasma decay curve).
This is indeed demonstrated by the two antiepileptic
drugs trimethadione andvalproicacid(Fig. 4). It should
be noted, however, that the peak drug levels will be
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strongly dependent on the rate, and not only the extent
of absorption. Thus, special drug formulations such as
"slowrelease" formulations willresult inbroad and low-
ered concentration-time peaks. The rate of absorption
is therefore of great significance when the teratogen-
icity of a drug is dependent on a particular threshold
concentration reached (e.g., as peak levels). On the
other hand, the rate of absorption is irrelevant when
the teratogenicity of a drug is dependent on the AUC
values obtained, regardless ofthe shape ofthe concen-
tration-time curvesunlesstherearechangesinfirstpass
elimination due to saturation. The significance of peak
druglevels vs. AUC values in regard to the teratogenic
response will be extensively discussed below.
Placental Transfer of Drugs
The rate oftransfer ofdrugs to the embryo and fetus
should clearly be differentiated from the extent ofdrug
transfer, since different factors determine these two
pharmacokinetic variables (Table 3). It has often been
generalized that drugs with high lipophilicity, low de-
gree of ionization, and molecular weights below 1000
are rapidly transferred across the placenta (51). Such
generalizations may not always be valid, which is dem-
onstratedjust for two cases. Valproic acid is present at
physiological pH in the ionized form to 99.9%; in spite
of this high degree of ionization, the transfer rate was
found to be rapid, and equilibration between maternal
plasma and gestational tissue was established within 30
min in the mouse (17). The highly lipophilic substance
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FIGURE 3. Volume ofdistribution Vd and maximal concentrations Cma,, of(left) valproic acid (46,47) and (right) trimethadione (48) in various
species. An oral dose of 50 mg/kg was used for valproic acid (except in man, 25 mg/kg), and an IV dose of 50 mg/kg for trimethadione
(except in man, oral). Note the relatively small interspecies variation of Vd and Cma,Ul) except for the relatively low Vd ofvalproic acid in
man because ofextensive plasmaproteinbindinginthis species (Fig. 7). A fulllistingofpharmacokinetic parameters ofthese two teratogens
is given elsewhere (46-48).
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FIGURE 4. Plasma concentration-time curves of (left) valproic acid following an oral dose in various species (50 mg/kg) (10,14,46,47,49,
50) and (right) trimethadione following a dose of50 mg/kg to various species (IV: mouse, hamster, rabbit, rat; oral: man). The right figure
was plotted from data reported by Tanaka et al. (48). Note the relatively comparable drug peak concentrations in spite ofthe drastically
different half-lives in the various species.
Table 3. Parameters determining the rate and extent of drug
transfer to the embryo.a
Drug transfer Parameters
Rate Lipid solubility of drugsb
Molecular weight ofdrugsb
Placental blood flow
Placental structure and function
Active transport ofdrugs
Extent PKa of the drug
Maternal/embryonic pH gradient
Protein binding of drugs
Active transport of drugs
aAdapted from Mirkin and Singh (51).
bAnd other physicochemical characteristics determining the diffu-
sion constants of drugs.
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (not ion-
ized) reached very low concentrations in the embryo
and fetus ofthe mouse, presumably because ofthe low
fat content ofthe conceptus (42). Thus, lipophilicity and
degree of ionization do not correlate in each case with
the rate or extent of placental transfer, respectively.
Active transport mechanisms have not clearly been
demonstrated to be ofmajor importance for the rate or
the extent of placental drug transfer except in a few
cases (52). Dencker (53) has recently shown that tre-
tinoin (all-trans-retinoic acid) may have specific binding
sites inthe embryo, particularly intheneuraltube area.
It has also been speculated that this compound is ac-
tivelytransported acrossthemouseplacentaviaspecific
binding proteins (21). Further experimental evidence
for the specific binding must be obtained in future stud-
ies.
The pH ofthe embryo or fetal blood canbe important
in regard to the extent of transfer of acidic and basic
drugs. The pH of fetal blood was shown to be lower
than maternal blood (51); consequently, the concentra-
tions offree drug (unbound to proteins) ofacidic drugs
such as valproic acid (54) will be lower in fetal than in
maternal blood. The reverse is true forbasic drugs such
as local anesthetic agents (55), where free drug concen-
trations in fetal blood can exceed maternal values, par-
ticularly in fetal acidosis.
SincethepH oftheearlymammalianembryoishigher
than maternal plasma, acidic drugs can accumulate in
these embryos during organogenesis which may be of
significance in regard to the teratogenicity ofthis class
of compounds (40,56). Examples of teratogens accu-
mulating in the early mammalian embryo include val-
proic acid and dimethadione in the early mouse and rat
embryo (40), salicylic acid (57), and methoxyacetic acid
in the rat embryo (40,76), thalidomide (a glutamic acid
metabolite) intherabbitblastocyst (58), and ahalothane
metabolite (probably trichloroacetic acid) in the mouse
embryo (59).
A study of18 metabolites and analogs ofvalproic acid
showed that the teratogenicity is a very specific prop-
erty ofthis class ofweak acids (60). Only the 4-en me-
tabolite (2-propyl-4-pentenoic acid) exhibits teratoge-
nicity comparable to the parent drug. A shift of the
double bond to the 2-position (2-en-valproic acid; 2-pro-
pyl-2-pentenoic acid) as well as furtherbranchingofthe
2-position (the a-carbon is now quartenary) essentially
abolishes teratogenicity (60) (Fig. 5). Since latter com-
pounds exhibit anticonvulsant activity (61), the possi-
bility of developing a structural analog to valproic acid
with good anticonvulsant activity, but low teratogen-
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FIGURE 5. Incidence of exencephaly (% of live fetuses) of various
metabolites ofvalproic acid and related carboxylic acids. Only the
4-en-metabolite is ofteratogenicity comparable to the parent drug
(60).
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FIGURE 6. Schematic representation of the influence of maternal
plasma protein binding on the embryonic drug exposure. Only the
free plasma concentration is expected to equilibrate with embry-
onic tissue.
icity (62) exists. Furthermore, these substances should
provide valuable tools for a study of the exact nature
ofthe structural requirements for teratogenic activity.
Exposure of the embryo will also be dependent on
the route of drug administration. Administration IP
oftenresults inhigherconcentrations inthe embryo and
more extensive teratogenic effects ascompared toother
application regimens (see above).
Although morphological studies (134) have defined
differences between several mammalian placentas and
their comparative development, these results did not
provide informationinregardtothepossibledifferences
in the function ofthese placentas. Thus, essentially we
do not know how and if differences between the pla-
cental structures influence the transfer ofdrugs to the
embryo in the various species. Comparative studies on
the placental transfer of drugs in different species at
comparable gestational stages are available infewcases
only.
Digoxin readily crossed the rodent and human pla-
centa, however, the ovine placentawas surprisinglyim-
permeable to this drug (51). Gentamycin was efficiently
transferred by the human, but not the goat placenta
(63). These comparative studies were performed during
the fetal gestational stages.
It becomes increasingly clear, however, that even
substances which are closely related from a structural
viewpoint candiffergreatlyinregardtoplacentaltrans-
fer and teratogenicity. This was recently demonstrated
in the case of 13-cis- and all-trans-retinoic acids, which
show drastic differences in regard to placental transfer
in the mouse (21) that may explain the greatly differing
teratogenic potencies of these two retinoids. Also the
teratogenicity of benzodiazepins in the rat was shown
to be related to the relative extent ofplacentaltransfer:
nitrazepam showed much higher teratogenicity as well
as placental transfer as compared to diazepam (64). It
was also reported that the relative teratogenic potency
of synthetic and naturally ocurring steroids in the rat
was related to the relative exposure of the embryo to
these two compounds (65).
There are also some examples which demonstrate
thatthe intrinsic sensitivities ofthe embryo cangreatly
vary among different species. The monkey was shown
to be less sensitive to methotrexate (135) and hydrox-
yurea (136) thantherat: relatively smallmaternal doses
of these drugs produced a teratogenic effect in the rat
in spite of low embryonic concentrations, while even
high embryonic levels in the monkey embryo elicited
only a limited teratogenic effect.
Maternal Plasma Protein Binding
and Placental Transfer
It is an attractive, but still unproven hypothesis that
the extent of protein binding will be an important de-
terminant ofplacental drug transfer and teratogenesis,
since only the free drug (unbound to macromolecules)
is expected to equilibrate with the embryo (Fig. 6).
Bindingofdrugstomacromoleculesinbloodorplasma
(commonly termed plasma protein binding) ortissues is
a major factor in drug distribution. Ifdrug tissue bind-
ing exceeds plasma proteins binding (often observed
with basic drugs), then large distribution volumes (ad-
justed for body weight) result (Vd > 1 L/kg). If the
reverse is true (as with many acidic drugs), small dis-
tribution volumes are obtained (Vd < 0.4 L/kg). If a
drug (such as ethosuximide, trimethadione, or dimeth-
adione) is not bound to either plasma ortissue macrom-
olecules, or if plasma and tissue binding are similar
(phenytoin, diazepam), then a drug distributes rather
uniformly throughout the organism (Vd 0.5-1 L/kg).
It has been noted that tissue binding may be rather
similaracross species, whileplasmaproteinbindingcan
vary greatly and unpredictably. The plasma protein
binding ofdrugs is often lower in experimental animals
than in man which is demonstrated in the case of val-
proic acid in Figure 7. This may result in somewhat
larger distribution volumes ofdrugs in animals as com-
pared to man (Fig. 3, left). Exceptions to this rule,
however, do exist (33): the protein binding of indo-
methacin in the rat is 99%, in man 97%. This extensive
protein binding may partly explain the relatively long
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FIGURE 7. Protein binding (expressed as free fractions x 100) of
valproic acid in serum (reconstituted from lyophilized material
commercially available) of various species. Added total concen-
tration was 100 ,ug/mL. Note the much higher free fractions in
mouse and hamster serum as compared to primate serum. From
Nau (47).
half-life of this drug in the rat (8-22 hr) which even
exceeds that in man (4 hr).
Several lines of recent evidence support the hypoth-
esis that plasma protein binding may be a major and
important factor determining the extent of placental
transfer and possibly also the teratogenicity of highly
protein-bound drugs. The transfer of drugs such as di-
azepam, valproic acid, salicylic acid and several local
anesthetic agents to the human fetus was shown to be
determined by the gradient between maternal and fetal
plasma protein binding (Table 4). The total concentra-
tions ofvalproic acid, diazepam, and salicylic acid were
higher in fetal blood than in maternal blood (Table 4),
because ofmore extensive fetalplasma protein binding;
maternal plasma protein binding of these drugs was
diminished because of increased free fatty acid levels
actingasdisplacers. Thesituationwasreversed forlocal
anesthetic agents such aslidocaine andbupivacaine (low
fetal concentrations because oflowfetalbinding) (Table
4). The free (unbound and possibly active) concentra-
tions of all these compounds are expectedly similar on
both sides ofthe placenta. Chlorthalidone reaches very
low levels in fetal blood, probably because of low con-
Table 4. Transfer ofdrugs during fetal development in the
human.
Fetal/maternal plasma
concentration ratio Drug Reference
> 1 Diazepam (66,67)
Valproic acid (54,68)
Salicylic acid (69,70)
Nalidixic acid \1)
0.5-1 Most drugs
< 1 Dicloxacillin (72)
Erythromycin (73)
Chlorthalidone (74)
Lidocaine, bupivacaine (55)
Tubocurarine, suxamethonium (75)
Cimetidine (76)
ELIMINATION OF DRUGS
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FIGURE 8. Schematic representation of drug elimination; the qual-
itative patterns and quantitative rates are differentiated.
centrations ofcarbonic anhydrase in fetal erythrocytes.
The relatively low levels ofdicloxacillin, erythromycin,
and cimetidine have not been explained (Table 4). Be-
cause ofmore extensive protein binding ofvalproic acid
in the rat as compared to the mouse, the exposure of
the rat embryo with this drug was found to be lower
than ofthe mouse embryo (77). These results may help
to explain the increased sensitivity ofthe mouse in re-
gard to valproic acid teratogenesis. Interestingly,
neural tube defects were produced in the two species
(mouse, hamster) with the lowest maternal protein
binding (highest free concentration available for pla-
centaltransfer). Alsotheresults ofinvitro experiments
with valproic acid and its more highly bound active me-
tabolites suggest that the free concentrations (in this
case in the culture medium) and not the total concen-
trationsarerelevantdeterminantsoftheconcentrations
in the embryo as well as the teratogenicity observed
(78). The comparative teratogenicity of salicylic acid in
rat and rhesus monkey could also be related to the ex-
tent ofmaternal protein binding and placental transfer
(137). This drug was more teratogenic in the rat as
compared to the monkey, probably because of lower
maternal plasma protein binding and more extensive
placental transfer in the rat as compared to the monkey
(137). Furthermore, administration of bacterial endo-
toxin was shown to reduce the maternal plasmaprotein
binding ofsalicylic acid which resulted in increased pla-
cental transfer and teratogenicity ofthis drug (79).
While all these results provide circumstantial evi-
dence for the importance ofmaternal protein binding in
teratogenesis, it appears ofimportance to study factors
which can modify maternal protein binding, e.g., coad-
ministration of other drugs, hormonal and nutritional
factors, stress, etc. Some of these factors have been
shown to decrease maternal plasma protein binding
which may result in increased drug exposure of the
embryo (66-70, 80).
Drug Elimination
Drugs are eliminated predominantly by metabolism
in the liver and excretion via bile and urine (Fig. 8). It
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Table 5. Pattern of drug metabolism in rat and monkey as
model for man.a
Percent of drugs studied
Other
nonprimates
Pattern as model (dog, rabbit,
for man Rat guinea pig) Rhesus monkey
Good 29 32 73
Fair 12 27 19
Poor 20 9 4
Invalid 42 32 4
aData collected for 32 substances by Caldwell et al. (82) and ref-
erences therein.
must therefore be differentiated between the qualita-
tive pattern of metabolites produced predominantly in
the liver and the quantitative rates ofdrug elimination
and excretion, predominantly via hepatic metabolism
and renal and biliary excretion.
Pattern of Drug Metabolism
Drug metabolism is widely considered to be an im-
portant reason for the species differences observed in
regard to the toxic response to drugs. The pattern of
metabolites produced is often complex and unpredict-
able, although some generalizations have been made for
some metabolic pathways: the rat and the dog are par-
ticularly efficient biliary exeretors; glucuronic acid con-
jugation is usually deficient in the cat; the dog is a poor
acetylator; and the rat and guinea pig are poor hydrox-
ylators of aliphatic amines and aromatic amides, re-
spectively (81,82). The old world monkey resembles
manmostcloselyindrugmetabolicterms. Acompilation
of the metabolic pattern of 32 compounds showed that
the rhesus monkey was a good model for man in 73%
of cases and an invalid model in only 4% of cases (Table
5).
On the other hand, the pattern of valproic acid me-
tabolites was rather similar in a variety of species, al-
though also here some quantitative differences occur
between the mouse, rat, dog, monkey, and man (50). It
is therefore highly unlikely that the species differences
observed in valproic acid teratogenesis are the result
of different metabolic patterns in the species investi-
gated.
Nevertheless, it is tempting to speculate that, if ma-
jor interspecies differences occur in regard to drug me-
tabolism, such differences may be ofsignificance for the
teratogenic response. Indeed, indirect evidence has
been obtained for the responsibility of reactive metab-
olites for the teratogenicity of phenytoin (83) and tha-
lidomide (84). However, direct proofthat differences in
metabolic pattern or metabolic activation pathways
("toxification") are responsible for species differences in
theteratogenic drug response is notavailable upto now.
In other words, it could not be demonstrated that a
particular drug metabolic pathway or the deficiency of
a pathway is the reason for the teratogenicity of a drug
in one species, and for the lack of response in another.
Indirect, although very interesting evidence forthe im-
portance ofreactivemetabolites ofthalidomide was pre-
sentedbyGordonetal. (84)usinganinvitrolymphocyte
system. These authors found thatmicrosomesfromrab-
bit, monkey, and man (sensitive species), but not from
the rat (insensitive species) can increase the toxicity of
thalidomide in this lymphocyte system. Furthermore,
the addition ofepoxide hydrolase decreased the toxicity
ofthalidomide. These results indicate that the putative
toxic metabolite ofthalidomide-produced by the rab-
bit, monkey and man but not the rat-may be an epox-
ide (84). Ifthese promising results can be extrapolated
tothe embryoin orderto explainthe species differences
of thalidomide teratogenicity, they must await further
studies.
In a recent report, Finnell (85) has speculated that
the intraspecies variation ofphenytointeratogenicity in
the mouse may be the result of differing epoxide hy-
drolase activities of the various strains. This enzyme
may be responsible forthe detoxification ofthe putative
epoxide metabolite of phenytoin which could conceiva-
bly be the ultimate teratogenic metabolite. It should be
mentionedthatotherstudieshaveimplicated the parent
drug and not a metabolite or the teratogenic agent (86);
the phenytoin metabolism to the p-hydroxy and dihy-
drodiol metabolite, both likely to be produced via an
epoxide intermediate, did not differ between a suscep-
tible (A/J) and resistant (C57 BL/6J) strain ofmice (86).
Furthermore, the marked intraspecies differences of
the mouse with respect to phenytoin teratogenicity
could not be explained by Atlas et al. (87), by genetic
differences in phenytoin elimination rates in vivo or by
liver microsomal metabolism in vitro.
Further evidence for the importance of the epoxide
detoxification pathway in phenytoin teratogenesis was
obtained by Spielberg's group (88) in clinical studies.
These authors incubated lymphocytes from patients in
the presence ofphenytoin which was activated in vitro
by a microsomal enzyme preparation. Lymphocytes
from children, which had been exposed to maternal
phenytoin in utero and who had birth defects exhibited
increased susceptibility to activated phenytoin in vitro.
There is a major species difference in regard to the
presence of the hepatic cytochrome P-450 enzyme sys-
tem in the fetus: primate species have considerable
amounts of these enzymes, while nonprimate fetuses
(and embryos) have none or have them only to a minor
degree (89,90,108). Since this enzyme system might be
responsible for the toxification or detoxification of a
number ofdrugs, these findings are ofconsiderable po-
tential importance. However, such pathways have not
been related to species differences in the teratogenic
response. Most importantly, most major malformations
are produced during early gestation (less than 8 weeks
after conception in man) and studies with embryonic
tissues during that period in primate species including
man are essentially lacking. Should the embryonic cy-
tochrome P-450 system prove to be responsible for the
activation ofcertain drugs to proximate orultimate ter-
atogens, then non-human primate species would be the
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preferred species for testing such substances, if this
enzyme system should indeed be present in the embryo
at the relevant early gestational periods (3,5).
StudiesbyKastneretal. (94) showedthattheisolated
and reconstituted cytochrome P-450 can be successfully
incorporated into the in vitro limb bud system.
Studies by Juchau and co-workers (91) showed that
some xenobiotic-metabolizing enzymes can indeed be
induced in the early rodent embryo invivo. Subsequent
in vitro culture experiments in the presence of N-hy-
droxy-2-acetaminofluorene indicated that this com-
pound was more toxic to the preinduced embryos than
to control embryos. Also the production ofmetabolites
of this substance by preinduced embryos in vitro was
demonstrated.
In a recent study, Flint and Brown (109) showed the
presence ofboth constitutive and inducible levels ofcy-
tochrome P-450 isozymes in cultured rat embryo limb
cells by staining with specific antibodies. The implica-
tion ofthese findings in regard to the toxicity ofpheny-
toin, cyclophosphamide and triazoles was discussed by
these authors whoconvincingly showed thatrat embryo
cells are capable of xenobiotic metabolism during or-
ganogenesis.
Numerous studies have indicated that cyclophospha-
mide mustbe activated by cytochrome P-450 dependent
enzymes to teratogenic metabolites; the reader is re-
ferred to a recent comprehensive review (98). Labeling
with stable isotopes afforded a convenient way to iden-
tify the metabolic pathways leading to the proximate
or ultimate teratogenic metabolites (92).
Another related enzyme system, the cytochrome P1-
450, P-448 or aryl hydrocarbon hydroxylase (AHH), re-
sponsible for the activation of polycyclic aromatic hy-
drocarbons, is much more ubiquitously distributed in
various tissues and also was shown to be present in the
early embryo (93). Studies in mice have shown that the
affinities ofthe Ah-receptor in the embryos can be cor-
relatedwiththeincidence ofteratogenicity. Micehaving
a high affinity Ah receptor (C57 BL/6N) are much more
susceptible to AHH induction and teratogenicity after
IP administration of benz[a]pyrene than mice having a
poor affinity Ah receptor (AKR/J or DBA/2N)(95). In-
terestingly, the teratogenicity of benz[a]pyrene was
found to be lower in responsive than in nonresponsive
strains of mice following oral application of the toxin.
Apparently, extensive first-pass metabolism after oral
intubation reduced the amount ofthe toxinreachingthe
embryos in the responsive strain, but not the nonre-
sponsive strain of mice (96).
Placental AHH may play a protective role for em-
bryonic and fetal development. In a study involving
smokingwomenitwasfoundthatplacentas fromnormal
infants contained high levels ofAHH activity, whereas
placentas from abnormal infants had significantly lower
AHH activities (97). Thus, the AHH-related enzymes
may detoxify polycyclic aromatic hydrocarbons derived
from cigarette smoke.
Pretreatment with agents inducing orinhibitingdrug
metabolism have provided some information on the im-
portance of metabolic activation in teratogenesis.
Phenobarbital and barbital were shown to increase the
teratogenicity of aminopyrine, furylfuramide, and te-
trahydrocannabinolpossiblybyenhancingthemetabolic
pathway leading to the proximate or ultimate terato-
genic agent (Table 6). On the otherhand, phenobarbital
pretreatment was shown to decrease the teratogenicity
of valproic acid, and pretreatment with P-naphthofla-
vone reduced the teratogenicity of caffeine. Results of
pretreatment experiments are oftendifficulttoevaluate
because inducing or inhibiting agents cannot only mod-
ify the production of a particular metabolite, but also
its further biotransformation. In this regard, polychlo-
rinated biphenyl pretreatment was shown to increase
the teratogenicity of cyclophosphamide in the mouse,
but to decrease the teratogenicity of this drug in the
rat (Table 6). Apparently, the balance between toxifi-
cation and detoxification pathways ofcyclophosphamide
are differently affected by phenobarbital in these two
species. Precise measurements ofthe parent drug and/
or their putative active metabolites in the embryo will
be necessary to decide ifthe parent drug or aparticular
metabolic pathway can be related to teratogenesis.
The conclusion that valproic acid itself is the terato-
genic agent (Table 6) is consistent with the teratogenic
activity of this drug in vitro (15,78) where little meta-
bolic activity canbe expected. Furthermore,druglevels
were high, but the metabolite concentrations were very
low in the embryo (17). Also, the drug levels following
various administration regimens (oral, subcutaneous,
IP, minipump infusion) could be related to the terato-
logic response (17). All these data taken collectively
pointtothe drug astheultimateorproximateteratogen
(17).
Rates of Drug Elimination
It becomes increasingly clear that most drugs are
eliminated much more rapidly in experimental animals
thaninman. Thisistruebothforhydrophiliccompounds
which are predominantly excreted via kidney or bile,
and for lipophilic drugs which are extensively metabo-
lized (Table 7).
Small laboratory animals have relatively larger body
surface area/body weight ratios than man (Table 8).
Because of this relatively large body surface area, in-
creased metabolic functions to maintain body temper-
ature is required in laboratory animals. It has been
shown that many biological characteristics such as res-
piratory rate, long volume, kidney and liver size, heart
rate and blood flow rates can be more readily related
to the body surface area than to the body weight. An
inverse relationship was found between the longevity
ofaspecies andthe activityoftheeliminationprocesses.
Such concepts have proved useful for a comparison
ofthetoxicityofawiderange ofanticanceragentswhich
are not metabolized and can be effectively excreted be-
cause of the presence of polar groups. It is quite rea-
sonable that the toxicity ofanticancer agents (115) can
be correlated with the doses calculated on amg/m2basis
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Table 6. Effect of pretreatment of experimental animals on the teratogenicity and pharmacokinetics of some drugs.
Drug
Caffeine
Ethanol
Valproic acid
Tetrahydrocannabinol
Aminopyrine
Furfurylamide
Cyclophosphamide
Species
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Pretreatment
,B-Naphthoflavone
4-Methylpyrazole
Phenobarbitala
Phenobarbital
Phenobarbital, barbital
Phenobarbital
Mouse PCBs
Rat PCBs
Effect on
teratogenicity
Decreased
Increased
Decreased
Increased
Increased
Increased
Possible explanation
Decreased drug level
Increased drug level
Decreased drug levels
Increased formation of
reactive (teratogenic)
metabolite(s)
Decreased Species-dependent effect
on metabolic balance
Increased between activation/deactivation
pathways
Phenytoin Mouse Phenobarbital Decreased Complex influence on (87,107,
3-Methylcholanthrene Unchanged activation pathways and 108)
SKF-525Ab Increased detoxification of putative
TCPOC Increased epoxide metabolite
DEMd Increased
aIn one dosing regimen (1 x 600 mg/kg SC on day 8, mouse) phenobarbital pretreatment (0.1% in drinking water from day 7-8) reduced
the incidence ofexencephaly from 61% to background levels (0-1.5%) (17). Epidemiological studies (retrospective) alsoindicatethatphenobarbital
comedication may reduce the incidence of spina bifida in the offspring of valproate-exposed human epileptics (Robert, Lindout, and Rosa,
personal communication).
b Inhibitor of cytochrome P-450 catalyzed reactions.
' Inhibitor of epoxide hydrolase.
d Glutathione-depleting substance.
Table 7. Half-lives of some drugs in various species.a
Predominantly Half-lives, hr
eliminated via
Drug Liver Kidney Mouse Rat Hamster Guinea pig Rabbit Dog Monkey Man
Phenytoin x 3-5 2-6 10-15 10-60
Phenobarbital x x 3 30-50 40-70 50-150
Primidone x x 1-3 1.7 2-3 2-10 10 3-17
Trimethadione x 0.7 1.5-2.6 1 1-2 8 20-24
Valproic acid x 0.8 0.3 1 1-4 0.7-3 12
Diazepam x 1 1 2.4 3 8 20-50
Hexobarbital x 0.3 1-2b 1 3 6
Antipyrine x 0.2-0.6 1-2b 2 0.9 1-2 1-2 12
Phenazon x 0.2 2 2 1 2 2 10
13-cis-Retinoic acid x 0.3 1 3-6 10-30
All-trans-retinoic acidc x 0.5-1 0.6-2 4-5
Cyclophosphamide x 0.2 0.7 0.2 0.5 0.7 7
Caffeine x 0.7 0.8 1.6 3.2 4.2
Digoxin x x 9 16 27 44
Phenylbutazone x 6 1-5 0.5-3 1-6 1-8 72
Oxyphenylbutazone 6 3 0.5-C 8 72
Flurobufene 0.4 0.6 3
Cefotetan (+)d + 0.2 0.3 0.5 1 1.3 3.4
Cefmetazole (+) + 0.1 0.1 1.5 1 0.5 1
Cefoperazone (+) + 0.2 0.2 1 0.7 2.4 2.5
Moxalactam (+) + 0.3 0.4 1 1 1 1.3
Cefpiramide (+) + 0.2 0.4 1.1 1.2 2.5 5
Cefazolin (+) + 0.2 0.4 0.4 1 0.8 1.5
aAdapted from data in the literature (46, 47, 110-113).
bLarge sex difference.
'Saturation kinetics.
d(+), biliary excretion of ,B-lactam antibiotics significant in rat, but usually very low in other species.
because these compounds interfere with growth pro-
cesses which can be related to the body surface area
and thus the activity of the metabolic processes. With
other classes of drugs such a close correlation cannot
be expected since they interfere with specific physio-
logical functions or produce some specific structural or
biochemical lesion in the target cells (110,111). In such
cases it can be expected that comparable drug concen-
trations in the various species should result in compa-
rable pharmacological and toxicological effects. This has
Reference
(99)
(100,101)
(17)
(102)
(103)
(104)
(105)
(106)
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Table 8. Body weights, surface areas and conversion factors of
dosing from mg/kg into mg/m2.
Dose
Body Surface area, Conversion equivalent/
Species weight, kg m2 factorab kgc
Mouse 0.02 0.0066 3.0 12.0
Rat 0.15 0.025 5.9 6.0
Dog 8 0.40 20 1.7
Monkey 3 0.24 12 3.0
Humans
Child 20 0.80 25 1.5
Adult 60 1.60 37 1.0
aLiterature data (114,115).
bTo convert a mg/kg dose in a given species into an equivalent
mg/M2 dose, multiply the dose by the conversion factor.
'Dose equivalent for the adult human is set as 1.0.
indeed been shown to be the case for barbiturates: in
spite of a 50-fold difference in rates ofmetabolism and
duration ofaction ofthese drugs, various animalspecies
and man recover from the effects ofthese drugs at sim-
ilar plasma levels (111). In teratology, such data are
essentially lacking at this time.
In Table 8 the factors for the conversion of mg/kg
doses to mg/m2 doses are listed for several species. If
the relationships above hold true, equieffective doses
(on a mg/kg basis) in mice, rats and rhesus monkeys
will be 12x, 6x, and 3 x higher than in man, respec-
tively. As demonstrated below, such factors should be
used with extreme reservations.
The elimination of drugs which are predominantly
metabolized is not only dependent on liver size and he-
patic blood flow-parameters which can be related to
body surface area-but also on specific enzymes or iso-
enzymes present. Therefore, predictions are very dif-
ficult, butalso here, man exhibits usuallylowerormuch
lower hepatic drug metabolizing enzyme activities than
the laboratory animals. A detailed comparison between
various enzyme activities in mouse, rat, hamster, and
man showed that man exhibited lower microsomal cy-
tochrome P450 dependent monooxygenase activities in
liver (and extremely low activities in lung) as compared
to the rodent species (116).
Walker (81) has demonstrated areasonably good cor-
relation between the relative monooxygenase activity
and the relative half-life of compounds predominantly
eliminated by monooxygenase attack. Such drugs
should be 5 to 30 times more persistent in man than in
the male rat.
Epoxide hydrolase activities, onthe otherhand, were
low in mouse and comparable in rat, hamster, and man.
Glutathione-S-transferase activities were lowin rat and
man and substantially higher in mouse and hamster
(116). Thesefewexamples showthatgeneralizations are
very difficult in this area and drug metabolism activity
will depend on the particular metabolic reaction, the
nature ofthe substrate, the possible influence ofinhib-
itors or inducers (Table 6), and in vivo, the availability
of the drug at the site of metabolism (e.g., liver con-
centrations, plasma protein binding, volume of distri-
bution).
It should, however, be noted that the generalization
thatanimalseliminatedrugsmoreormuchmorerapidly
than man does not always hold true, and a number of
exceptions exist (33): the elimination of indomethacin
was found to be slower in rat than in man, perhaps
because of more extensive protein binding in the rat;
zomepirac was also eliminated more slowly in rat than
in man, while the elimination of proxicromil and furo-
semide were about equal in both species.
Clearance and Half-life as
Parameters
Plasma (or blood) clearance (Cl) is the most appro-
priate parameter to characterize drug elimination. This
parameter, which denotes the total capacity of the or-
ganism to eliminate drugs, via metabolism and/or ex-
cretion, can best be calculated from the dose adminis-
tered (D), thefractionofdrugabsorbed (F)andthearea
under the concentration-time curve (AUC):
Cl = DF
AUC
On the other hand, the elimination half-life (tb) is de-
pendent not only on drug elimination, but also on the
drug distribution volume (Vd).
tj/2 = 0.69 (one plasma elimination phase)
Thus, a long (short) half-life is not necessarily related
only to low (high) drug clearance, but may additionally
be caused by a high/low volume of distribution. Also,
the kinetics of many drugs cannot be described by a
single-compartment model, but by a two- (or three-)
compartment model, where several phases of the
plasmaconcentration-time curve decaycanbe observed
(Fig. 2), described byt½,,c (distribution phase) and t
(elimination phase).
tl, 3 = 0.69 Cd,« (two plasma elimination phases)
The initial phase (a) ofrapid drugconcentration decline
in plasmaresults from distribution ofthe drug from the
central compartment into the peripheral compartment
(e.g., storagesitesintissues). Exceptionsherearehigh-
clearance drugs which are also eliminated during the a
phase. After distribution is complete, the plasma level
curve is described by the elimination phase (O) with
irreversible drug clearance. The precise value for the
,3-elimination half-life is sometimes difficult to obtain
because of the low concentrations present during this
elimination phase.
Although plasma (or blood) clearance values would
have some advantages over half-lives for the charac-
terization ofthe total capacity ofthe organism for drug
elimination, itwas decided to compile half-lives inTable
7 since this pharmacokinetic parameter gives a good
estimate for the duration ofdrug action and the extent
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ofdrug accumulation with a given multiple dosing reg-
imen.
Saturation Kinetics (Nonlinear
Pharmacokinetics)
If linear kinetics are followed, then the plasma con-
centrations and AUC values will be proportional to the
dose. It follows that nonlinear kinetics are obtained if
a linear relationship between dose and plasma concen-
trations (orAUC values) does notexist. Several reasons
may be responsible forthis nonlinearity with increasing
doses: (a) the first-pass effect becomes saturated;
(b) the plasma protein binding becomes saturated re-
sulting in increased volume of distribution and tissue
drug levels; (c) the hepatic and renal elimination ca-
pacities become saturated. All three factors may result
in an overproportional rise ofdrug levels (or AUC val-
ues) with increasing doses. Small increments in dose
may cause an unexpectedly large increase of the tera-
togenic response. Very steepdose-response curveswith
a pronounced threshold are the result which are indeed
often seen in experimental teratology.
Examples of drugs with pronounced saturation ki-
netics include all-trans-retinoic acid, salicylic acid, val-
proic acid, caffeine, coumarins, phenylbutazone, and
phenytoin (117). Interestingly, all-trans-retinoic acid
exhibits saturation kinetics already at very low doses
(118) (< 1 mg/kg, rat), while 13-cis-retinoic acid does
not (mouse).
Such considerations demonstrate most clearly the
value of concentration (or AUC value)-effect relation-
ships in addition to dose-effect plots for the evaluation
of teratogenicity tests (16). The considerable interin-
dividual variation observed even in closely controlled
laboratory animal species also call for the attempt to
correlate individual maternal drug exposure with the
teratologic response (119).
Peak Levels vs. AUC Values as
Teratological Correlates
Since, as discussed in detail above, many drugs ex-
hibit shorter half-lives in animals than in man, the phar-
macokinetics obtained during teratogenicity testing-
drugapplication once ortwice adayduring organogene-
sis-are grossly different from those seen in the human
therapeutic situation. In experimental animals, a series
of narrow and high drug concentration peaks are ob-
tained while in man drug fluctuations are usually much
less pronounced and blood levels are kept within agiven
therapeutic range. This is demonstrated in Figure 9
where the pharmacokinetics of valproic acid in man
(therapeutic doses) are compared with those in the
mouse (teratogenic doses) throughout the sensitive pe-
riod for interference with neural tube closure in both
species.
It can be observed from Figure 9 and the results of
calculations listed inTable9, thattheteratogeniclevels,
pgVPA/mI injection s.c.
FIGURE 9. Simulated plasma concentration-time curves of valproic
acid following a teratogenic drug administration regimen in the
mouse (resulting in 10% exencephaly formation) as compared to a
therapeutic drug administration schedule in man. Note the much
more drastic drug concentration fluctuations in the mouse as com-
pared to man. The time periods on the abscissa correspond to the
length ofthe organogenesis period sensitive to interference with
neural tube defect formations. From Nau (47).
particularly the free levels, are much higher in the
mouse than the "therapeutic peak levels" in man. On
the other hand, the AUC values during human therapy
are higherthanthe corresponding values obtained after
application ofteratogenic doses in the mouse (Table 9).
For a rational interspecies comparison or risk assess-
ment it is therefore essential to elucidate ifpeak levels
or the AUC values ("total exposure") are the relevant
factors determining the teratogenicity of this drug.
Wehavethereforeadministeredvalproicacidnotonly
by conventional injection regimens, but also at a con-
stant rate via subcutaneous implanted osmotic mini-
Table 9. Comparison of pharmacokinetic parameters ofvalproic
acid in mouse (teratogenic dose) with man (therapeutic dose).
Parameters Mousea Mana
Teratogenic dose 180b (4 x/24 hr) 30 (per 24 hr)
Cl (mL/hr 'x kg)' 1000 10
AUC (,ug/mL x hr)d 720 3000
Cmax (ug/tnL)
Total drug 230 100-150
Free drug 120 10-20
aLiterature data (14,16,46,47,50).
bIn this regimen SC doses were used which resulted in a significant
formation of exencephaly (10% of live fetuses).
cPlasma clearance.
dArea under plasma concentration-time curve.
eMaximal concentration.
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FIGURE 10. Comparison of two different administration regimens
ofvalproic acid which both result in 10% incidence ofexencephaly
formation in the mouse. The drug was either injected SC (220 mg
VPA-Na/kg x 12 hr; maternal peak plasma levels of270 ,ug/mL)
or infused by SC implanted minipumps (3800 mg VPA-Na/kg x
day; maternal steady-state plasma levels of 250 ,ug/mL). Calcu-
lated by probit analysis from dose/concentration-response curves
(16) and adapted from Nau (47).
pumps; in this way the teratogenic effects ofpeak drug
levels (injection regimen) can be compared with those
of steady-state concentrations (infusion regimen)
(14,16,120-122). Particular emphasis was given to the
formation of neural tube defects (exencephaly in the
mouse) since, as Table 1 shows, these malformations
may also be produced by valproic acid in man.
The dose-response curves for the formation of ex-
encephaly was shifted greatly to the right with the in-
fusion regimen as compared to the injection regimen.
Less pronounced shifts were obtained for the dose-re-
sponse curves for fetal weight retardation and embryo-
lethality. In fact, high rates of exencephaly with the
infusion regimen could only be observed within a very
narrow "dose window" not covered up by embryole-
thality. On the other hand, the concentration-response
curves were rather similar for both regimens. Here,
steady-state levels after infusion were compared with
peak levels after injection. These results indicate that
the total drug exposure, as measured by doses or AUC
values, was not the decisive factor in regard to valproic
acid-induced exencephaly formation in the mouse. A
particular threshold concentration must be reached
either by a series of short-lived drug concentration
peaks or by steady-state concentrations-to produce
the teratogenic effect in the embryo (Fig. 10).
These results should have important implications for
a rational interspecies comparison. As Table 9 shows,
the peak concentrations, particularly ofthe free drug-
are much higher in the mouse after teratogenic dose as
comparedtomanduringtherapy, implicatingsomemar-
gin of safety. On the other hand, a comparison of the
AUC values would have indicated that man is actually
exposed to valproic acid to a larger extent than the
mouse. It seems therefore prudent to suggest that the
peak drug levels which are still present in human ther-
apy(Fig. 9)shouldbereduced asmuchaspossibleeither
by dividing the daily dose or by using slow-release for-
mulations to minimize the teratogenic risk of antiepi-
leptic therapy with this drug.
A comparison ofthe pharmacokinetics as well as ter-
atogenicity ofcaffeine following injection ofsingle mas-
sive doses with the results obtained after multiple ap-
plication of divided doses suggest that the
teratogenicity of this drug is also related to peak con-
centrations (123,124).
Thesituationwithotherdrugsmaybequitedifferent.
We have recently observed that the teratogenicity of
cyclophosphamide can be related to the maternal AUC
and not the peak levels (125). There, it makes little
difference if a particular AUC value is reached with
narrow and high concentration peaks (injection) orwith
low steady-state concentrations for a prolonged time
(infusion).
Also the embryotoxicity of saliclate (126), cyanide
(127), arsenate (128), and tetracycline (129) has been
investigated following infusion of these substances. It
appearsthat embryotoxicityis produced bytheinfusion
ofthese compounds which couldindicate theimportance
of AUC values in regard to the teratogenic response,
although dose- and concentration-response relation-
ships of the injection and infusion regimens have not
been reported with these substances.
The administration of drugs via drinking water or
food is very convenient; however, the results obtained
are often difficult to interpret. Even if the presence of
drugs does not change the food and waterconsumption,
the relatively short half-lives of many drugs (Table 7)
and the variability offood and water consumption pre-
vents a controlled pharmacokinetic study. Plasma drug
levels will depend greatly on the time of food/water
intake in relation to the time of sampling (130).
Concluding Remarks
It is very unlikely that an animal species will ever be
found that will consistently metabolize and excrete
drugswiththe same rates and metabolicpattern as man
and is suitable for laboratory experimentation. We
should therefore accept that there are great differences
and ratherconcentrate to studythe significance ofthese
differences and their effects on the teratological re-
sponse which could greatly improve our present ex-
trapolation techniques. The example of valproic acid
discussed above clearly shows that it is not sufficient to
use doses, AUC values or peak levels for interspecies
comparison. We must first determine which pharma-
cokinetic parameter correlates with the teratogenic re-
sponse. If the AUC values (or doses) are the decisive
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factors (as with cyleophosphamide), then toxicity is re-
lated inversely to clearance ofthe drug (where usually
great differences exist between animals and man and
"scaling factors" such as those listed in Table 8 may be
useful). On the other hand, ifpeak drug levels (such as
the case with valproic acid) correlate with terato-
genicity, then the toxic response will be related to ab-
sorption and distribution phenomena (which are usually
not too different in the various species). If we do not
knowwhich parametertouseforcomparison, thencom-
pletely misleading results may be obtained (Table 9).
In this way interspecies comparisons will be based on
a more rational and scientific basis and the prediction
of the human response based on animal studies could
be improved.
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